Related Experiment Video
Updated: Jan 17, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Novel Pyrido[4,3‑d]pyrimidine Compounds as KRAS Inhibitors
1Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
None:
This highlight describes novel substituted pyrido-[4,3-d]-pyrimidine compounds as KRAS (Kirsten rat sarcoma viral oncogene homologue) inhibitors. The invention provides details about novel pyrido-[4,3-d]-pyrimidine compounds, their pharmaceutical composition, potential use, and treatment for KRAS-related diseases, such as various cancers.
Related Concept Videos
Inhibition of Cdk Activity
The Ras Gene
Ras is a...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Abnormal Proliferation
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

